ReviewCureus2026
Efficiency of Human Papillomavirus (HPV) Testing in Cervical Cancer Screening and Vaccination: A Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ailanthone as a novel AKT1 inhibitor that induces mitochondrial apoptosis and exerts anti-tumor activity in cervical cancer.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is one of the leading causes of female mortality in the world. However, since it has a long premalignant stage, cervical cancers can be prevented by early diagnosis or by regular screening. Over the years, conventional cytology has served as an excellent tool for diagnosis and early detection of cervical dysplastic lesions. However, it had a few drawbacks, which were overcome by the introduction of liquid-based cytology (LBC). LBC provided a relatively better efficiency. However, LBC necessitates high-end laboratory infrastructure, which is unavailable in resource-poor settings. Human papillomavirus (HPV) being the main etiology for causing cervical cancer, theoretically, cervical cancer can be prevented if vaccination against HPV is provided at an early age. Also, HPV testing, in contrast to cytology, does not depend on morphology for interpretation and is only based on the identification of HPV DNA or other viral markers. HPV detection thus provided less room for false positivity than cytology. In this review, the author will focus on the importance of HPV testing as a potential primary cervical cancer screening modality. Also, this review will discuss the advent of HPV vaccination with its role in cervical cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.